Navigation Links
ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver

arma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at http://www.viropharma.com .

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. .including those relating to the company's progress of its HCV clinical development program as well as its ability to develop an effective small molecule antiviral treatment for HCV disease. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements.. Conducting clinical trials for investigational pharmaceutical products is subject to risks and uncertainties. Further testing such as the ongoing Phase 2 clinical studies of HCV-796 with pegylated interferon, may not support any or all of the statements in this press release. There can be no assurance that ViroPharma's additional HCV studies will yield positive results, or that ViroPharma will be successful in gaining regulatory approval of any of its HCV product candidates. These factors, and other factors, including, but not limited to those described in ViroPharma's quarterly report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.

CONTACT: Vincent J. Milano, Vice President, Chief Operating Officer, ChiefFinancial Officer and Treasurer, +1-610-321-6225, or William C. Roberts,Senior Director, Corporate Communications, +1-610-321-6288, both ofViroPharma Incorporated

Web site:




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:6/30/2015)... 24, 2015 Research and Markets( http://www.researchandmarkets.com/research/pggcjf/global_endoscopy ... "Global Endoscopy Devices Market 2015-2019" report to ... market to grow at a CAGR of 5.53% ... devices market can be segmented into three based ... The market can be further segments in terms ...
(Date:6/30/2015)... SEATTLE , BERKELEY, Calif. ... 2015 CMC Biologics, Inc. , a ... antibodies and other therapeutic proteins, announced today that, as ... has completed the expansion of its North American manufacturing ... the addition of a single-use Bioreactor 6Pack™ facility.  The ...
(Date:6/30/2015)... , June 30, 2015 PharmaVentures ... advisor to Chip-Man Technologies Oy (CMT) on its divestment ... assets relate to CMTs world leading capabilities in cellular ... latest in a series of successful global deals in ... Fintan Walton , CEO, PharmaVentures, commented: ...
Breaking Medicine Technology:Global Endoscopy Devices Market 2015-2019 - Key Players are Boston Scientific, Johnson and Johnson, Medtronic, Karl Storz & Olympus 2Global Endoscopy Devices Market 2015-2019 - Key Players are Boston Scientific, Johnson and Johnson, Medtronic, Karl Storz & Olympus 3CMC Biologics Expands GMP Manufacturing Capacity in the United States 2CMC Biologics Expands GMP Manufacturing Capacity in the United States 3PharmaVentures Completes M&A Deal for Technology in the Stem Cell & Regenerative Medicine Sector 2
... March 24, 2011 A new program from American ... consumers regarding the price of advanced diagnostic imaging exams ... are performed, offering significant cost savings and increased satisfaction. ... care spending, there is a growing need for information ...
... PARSIPPANY, N.J., March 24, 2011 PDI, Inc. (Nasdaq: ... NASDAQ Stock Market Closing Bell on Tuesday, March 29, 2011, at ... PDI CEO Nancy Lurker will ring the Closing Bell together with ... "Ringing the NASDAQ bell is a particularly meaningful event for PDI ...
Cached Medicine Technology:American Imaging Management Promotes Affordability and Choice to Health Care Consumers 2American Imaging Management Promotes Affordability and Choice to Health Care Consumers 3American Imaging Management Promotes Affordability and Choice to Health Care Consumers 4
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... new YouTube video, “Fireside Convalescent Care Center.” The video informs community members of ... after continually seeing the need for those seeking care to be well informed ...
(Date:6/30/2015)... ... June 30, 2015 , ... The LIV Fertility ... fertility preservation and deciding the right age to pursue egg freezing. Statistics show that ... age of 35 — a 150 percent increase since the 1970s. , Sadly, for ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... in a new video, “Grand Terrace Health Care Center.” Each year, Medicare ranks ... help patients find the best facility for their needs. Grand Terrace prides itself ...
(Date:6/30/2015)... , ... June 30, 2015 , ... According to a ... 2007 to 2013 while heroin-related deaths more than tripled in the same period—leading a ... Novus Medical Detox Center , a leading Florida-based drug treatment facility, asserts that ...
(Date:6/30/2015)... ... June 30, 2015 , ... ADVOCATE, the premier provider ... awarded the exclusive billing agreements with Jackson Radiology Associates in Jackson, TN. ... proprietary suite of billing process software functionality called Experience Based Technology (EBTTM). ...
Breaking Medicine News(10 mins):Health News:Fireside Convalescent Hospital Proves Itself as a Leading Care Center in New Video 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 3Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 4Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 5Health News:Grand Terrace Health Care Center Announces Five-Star Rating in YouTube Video 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:ADVOCATE Wins Billing Agreements with Jackson Radiology Associates 2
... HealthDay Reporter , THURSDAY, Aug. 12 (HealthDay ... traffic jams and work deadlines may depend, in part, on ... research suggests. "The message is that father-son relationships are ... said study lead author Melanie Mallers, an assistant professor at ...
... for Environmental Education and Research is helping Heritage ... workers to create a pool of green collar ... energy efficiency. A handful of local and ... U.S. Labor Department Energy Training Partnership grant, awarded ...
... NEW YORK, NY August 12, 2010 The ... the previously announced late breaking clinical trials and first ... presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific ... of significant topics in interventional cardiovascular medicine. TCT 2010 ...
... Mozes HealthDay Reporter , THURSDAY, Aug. 12 (HealthDay ... reported among college students than a decade ago, as more ... and are open to getting help when they need it, ... medications by students to treat psychiatric illness has also risen ...
... Tufts Gerald J. and Dorothy R. Friedman School of ... School Symposium, November 5-6, 2010 in Boston and streaming ... examine the far-reaching implications of nutrition security, but what ... will come to present at the Symposium. Our ...
... investment of S$3 million is being pumped into tuberculosis ... group Institut Mrieux and its in vitro diagnostics company ... joint laboratory in Biopolis, Singapore aims to investigate and ... individuals at risk of TB disease development and disease ...
Cached Medicine News:Health News:Bond With Dad May Play Role in Whether Men 'Stress Out' 2Health News:Carnegie Mellon's Steinbrenner Institute helps grow green jobs 2Health News:CRF announces featured clinical trials to be presented at TCT 2010 2Health News:CRF announces featured clinical trials to be presented at TCT 2010 3Health News:College Campuses See Rise in Cases of Severe Mental Illness 2Health News:College Campuses See Rise in Cases of Severe Mental Illness 3Health News:Impressive lineup of speakers at Tufts nutrition conference 2Health News:A*STAR and Institut Merieux/bioMerieux invest S$3m ($2.2m) in tuberculosis research 2
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: